Micropharma Expedites Patent Portfolio to Protect Unique Probiotic Technology
Published: Sep 19, 2012
MONTREAL, Sept. 19, 2012 /PRNewswire/ -- Micropharma Limited, a pioneer in the development of innovative and effective probiotics, has filed a number of patents for its probiotic technologies. Probiotics bacteria that confer a health benefit to the host are being studied to determine if they may have a more significant role in helping to maintain and improve health and wellness through the gut. And emerging science is evaluating whether supplementing the microbiome (gut bacteria) with probiotics can play a role in health and certain chronic diseases such as heart disease.
"Micropharma has invested significantly over the past several years in research and development to ensure our probiotic products will deliver on their promises," said Ryan Jones, president and chief executive officer, Micropharma. "By patenting our products like Cardioviva, it helps us guarantee to consumers that they will get a rigorously tested, proven probiotic product."
The probiotics market continues to grow at 15 percent, and Micropharma is a leader in the development of a new era of these products that require significantly more insight, research and investment.
"Micropharma's investments in innovation put us on the cutting edge of the probiotics market," said Dr. Chris Wahl, director of business development, Micropharma. "We have several new dietary products in development that will have a tremendous positive impact on health when used as part of a healthy diet and lifestyle."
About Micropharma Limited
Micropharma Limited, a pioneer in the development of innovative and effective probiotics, is launching a portfolio of natural supplements and food ingredient solutions aimed at addressing specific health markers to help maintain and improve health and wellness. Micropharma is specifically focused on products that address the healthy and natural metabolic balance and functioning of the microbiome, its resulting impact in the body, and improving human health. The company will out-license these products to partners for commercialization in the medical food, consumer healthcare, and food ingredient markets.
Micropharma's proprietary technology platform is ProSelect, a proprietary collection of bacteria, tools, high-throughput assays, and preclinical studies designed to screen and select bacteria for well-defined phenotypic traits that target metabolic pathways recognized as having therapeutic potential. Micropharma uses its novel fermentation and optimization techniques to activate genes and express traits of the organism that enhance the natural gut environment. Micropharma's ProSelect enabling technology has built an intellectual property (IP) and product portfolio estate. For more information, visit micropharma.net.
SOURCE Micropharma Limited